Ezogabine treatment shown to reduce motor neuron excitability in ALS patients

(Massachusetts General Hospital) Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine at the Motor Neurone Disease Association annual meeting. The trial met its primary goal of measuring a reduction in motor neuron excitability in people with ALS.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news